Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending August 2012. The report serves as a notification of transactions involving directors, persons discharging managerial responsibility (PDMRs), or connected persons, specifically regarding the US Retirement Savings Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of specific personnel transactions rather than a financial performance report.
Material Changes
The filing details an increase in the notional allocation of GSK American Depositary Shares (ADSs) within the US Retirement Savings Plan following a revaluation of the cash element. The transactions occurred on August 9, 2012, at a price of $46.69 per ADS.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It strictly reports compliance with Disclosure and Transparency Rule 3.1.4R(1)(a) and (c).
Important Facts for Investors
- Transaction Type: Notional allocation increase in the US Retirement Savings Plan.
- Transaction Date: August 9, 2012.
- Share Price: $46.69 per ADS.
- Individuals Involved:
- Dr M M Slaoui (10 ADSs) and Connected Person Dr K Slaoui (9 ADSs).
- Mr W C Louv (16 ADSs).
- Dr D Pulman (28 ADSs).
- Mr E J Gray (21 ADSs).
- Mrs D P Connelly (1 ADS).
- Financial Impact: No direct financial impact on company operations or consolidated financial statements is disclosed in this filing.